Last updated: February 19, 2026
What Is the Drug Associated with NDC 00009-3448?
NDC 00009-3448 corresponds to Doxil (liposomal doxorubicin HCl), a chemotherapy agent used primarily for ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma, and other malignancies. Doxil is a liposomal formulation of doxorubicin designed to improve drug delivery and reduce toxicity.
Market Size and Drivers
Incidence and Prevalence
- Ovarian cancer: Approximately 19,880 new cases in the U.S. annually[1].
- Kaposi's sarcoma: About 4,400 cases in the U.S., mostly AIDS-related[2].
- Multiple myeloma: Approximately 34,470 new cases in the U.S. annually[3].
Total addressable patient population in the U.S. exceeds 58,000 per year. Globally, these numbers multiply, particularly in emerging markets.
Market Dynamics
- Treatment landscape: Doxil is often used after progression on first-line therapies, usually as a second-line or later treatment.
- Regulatory status: Doxil was approved in 1995 by the FDA, with expanded indications for multiple cancers over time.
- Adoption: Market penetration has plateaued in mature markets due to competition from biosimilars and other chemotherapies; however, Doxil remains a standard treatment for specific indications.
Competitive Landscape
| Drug |
Type |
Year Approved |
Indications |
Market Share (Estimated) |
| Doxil (liposomal doxorubicin) |
Liposomal anthracycline |
1995 |
Ovarian, Kaposi's sarcoma, multiple myeloma |
60% of liposomal anthracycline use[4] |
| Myocet |
Non-liposomal doxorubicin |
2000 |
Breast cancer (approved in EU) |
Limited in U.S. |
| Generic doxorubicin |
Traditional |
1970s |
Various |
Increasing presence |
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP) for Doxil varies widely based on supplier, supply chain, and negotiated discounts.
- Typical list price: Approximately $2,500 to $3,000 per 20 mg vial[5].
- Treatment course: A standard course may involve multiple vials (e.g., 4-6), leading to total costs of $10,000 to $18,000.
Price Factors
- Market competition: Biosimilar development pressures could result in price erosion.
- Manufacturing costs: Liposomal formulation adds complexity; any supply chain disruptions can influence price.
- Regulatory actions: Patent expirations or exclusivity periods affect pricing power.
Price Projections (Next 5-10 Years)
| Year |
Expected Price Range |
Driving Factors |
| 2023 |
$2,500–$3,000 |
Stable market, limited biosimilar competition |
| 2025 |
$2,300–$2,800 |
Patent expiries or biosimilar entries in select markets |
| 2030 |
$2,000–$2,500 |
Increased biosimilar penetration, policy shifts |
Note: Prices are in nominal USD and account for typical discounts and rebates.
Regulatory and Patent Outlook
- Patent status: Doxil’s core patents expired in 2015 in the U.S., opening the door for biosimilar competition.
- Biosimilar development: Multiple firms have pending applications; FDA approval will influence future pricing and market share.
- Pricing policies: Budget constraints and value-based pricing models may drive negotiations downward.
Key Market Opportunities and Risks
Opportunities:
- Growing use in rare cancers and combination therapies.
- Expansion into previously untreated or minimally treated patient populations.
- Entry of biosimilars or generics, which could reduce prices.
Risks:
- Patent challenges or legal disputes.
- Competitive approval of cheaper biosimilars or new therapies.
- Regulatory reimbursement policies that favor cost-effective options.
Summary
Doxil remains a relevant chemotherapeutic agent with limited but stable market demand, primarily driven by existing indications. Pricing holds steady but is susceptible to downward pressure from biosimilars and regulatory changes. The next decade may see significant price reductions if biosimilars or generics are successfully launched.
Key Takeaways
- The U.S. market for Doxil involves roughly 58,000+ eligible patients annually.
- Current list prices hover near $2,500–$3,000 per vial.
- Market share remains significant but could decline due to biosimilar competition.
- Price projections suggest a gradual decline to around $2,000–$2,500 per vial by 2030.
- Patent expirations and biosimilar development are primary factors shaping future pricing trends.
FAQs
1. Will biosimilar drugs significantly lower the price of Doxil?
Yes. Biosimilar approvals and market entry typically reduce prices by 20-40% within 3-5 years.
2. How does Doxil compare to other treatments in efficacy?
Doxil offers a beneficial safety profile due to liposomal delivery but generally has similar efficacy to other anthracyclines; it is favored for certain indications due to reduced cardiotoxicity.
3. Are there upcoming regulatory changes that could impact prices?
FDA approval of biosimilars and reimbursement policies favoring generics could exert downward pressure.
4. What are the main barriers to biosimilar entry?
Manufacturing complexity, patent litigation, and limited market size for some indications.
5. Is Doxil still reimbursed at premium rates?
Reimbursement varies by payer and negotiated contract but generally aligns with other chemotherapies, with specific adjustments based on formulary placement.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] SEER Cancer Statistics Review, 2014.
[3] International Myeloma Foundation. (2022). Myeloma Statistics.
[4] Market Research Future. (2021). Liposomal Doxorubicin Market Analysis.
[5] Red Book Online. (2023). Wholesale Drug Prices.
